1
|
Jung J, Kim K, Kim C, Jung MH, Kim Y, Jang SH, Ko DW, Jang HM, Cho WJ, Kim YJ. Design and thermal-hydraulic analysis of multi-target system with 100 MeV proton linear accelerator for the production of 67Cu and 68Ge radioisotopes. Appl Radiat Isot 2024; 211:111415. [PMID: 38936285 DOI: 10.1016/j.apradiso.2024.111415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2024] [Revised: 06/01/2024] [Accepted: 06/19/2024] [Indexed: 06/29/2024]
Abstract
Radioisotopes are widely used in the fields of medicine, science, and industry. The growing demand for medical radioisotopes has driven research on alternative production methods. In particular, both isotopes of 67Cu and 68Ge play vital roles in the medical environment in many countries to be used in the radio-immunotherapy and the positron emission tomography imaging, respectively. This study designed a multi-target system consisting of two Zn and one Ga2O3 plates to enable simultaneous production of the medical radioisotopes 67Cu and 68Ge using 100 MeV proton beams. To understand the thermal effect on the multi-targets, we examined the distribution of energy absorbed in each solid plate target when exposed to an accelerated proton beam through the thermal-fluid analysis based on ANSYS simulation. For confirming thermal stability for two Zn targets and one Ga2O3 target, the modified water flow path inside the multi-target system was designed effectively with the controlled distribution of multiple sub-holes between main inlet and the following four channels. It was confirmed that the newly designed multi-target system of Zn and Ga2O3 solid plates shows higher thermal stability than the case of uniform distribution of water inlet, which means it could be exposed to a higher current beam of 7.57% to decrease the processing time.
Collapse
Affiliation(s)
- Juwon Jung
- Department of Mechanical Engineering, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, South Korea
| | - Kibaek Kim
- Department of Mechanical Engineering, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, South Korea
| | - Chorong Kim
- Particle Beam Research Division, Korea Atomic Energy Research Institute, 181, Mirae-ro, Geoncheon-eup, Gyeongju-si, Gyeongsang buk-do, 780-904, South Korea
| | - Myung-Hwan Jung
- Particle Beam Research Division, Korea Atomic Energy Research Institute, 181, Mirae-ro, Geoncheon-eup, Gyeongju-si, Gyeongsang buk-do, 780-904, South Korea
| | - Yoon Kim
- Department of Mechanical Engineering, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, South Korea
| | - Se-Hwan Jang
- Department of Mechanical Engineering, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, South Korea
| | - Dong-Woo Ko
- Department of Mechanical Engineering, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, South Korea
| | - Hye Min Jang
- Particle Beam Research Division, Korea Atomic Energy Research Institute, 181, Mirae-ro, Geoncheon-eup, Gyeongju-si, Gyeongsang buk-do, 780-904, South Korea
| | - Won-Je Cho
- Particle Beam Research Division, Korea Atomic Energy Research Institute, 181, Mirae-ro, Geoncheon-eup, Gyeongju-si, Gyeongsang buk-do, 780-904, South Korea.
| | - Young-Joo Kim
- Department of Mechanical Engineering, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, South Korea.
| |
Collapse
|
2
|
Nabatilan A, Thomas Morgan M, Netzer S, Fahrni CJ. Selective removal of copper from complex biological media with an agarose-immobilized high-affinity PSP ligand. J Biol Inorg Chem 2024; 29:531-540. [PMID: 39066798 DOI: 10.1007/s00775-024-02065-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2024] [Accepted: 06/20/2024] [Indexed: 07/30/2024]
Abstract
The elucidation of metal-dependent biological processes requires selective reagents for manipulating metal ion levels within biological solutions such as growth media or cell lysates. To this end, we immobilized a phosphine sulfide-stabilized phosphine (PSP) ligand on agarose to create a resin for the selective removal of copper from chemically complex biological media through simple filtration or centrifugation. Comprised of a conformationally preorganized phenylene-bridged backbone, the PSP-ligand binds Cu(I) with a 1:1 stoichiometry and exhibits a pH-independent Cu(I) dissociation constant in the low zeptomolar range. Neither Zn(II), Fe(II), nor Mn(II) interact with the ligand at millimolar concentrations, thus offering a much-improved selectivity towards copper over other commonly employed solid-supported chelators such as Chelex 100. As revealed by X-ray fluorescence elemental analysis, the immobilized chelator effectively removes copper from cell culture growth media and cell lysate isolated from mouse fibroblasts. In addition to preparing copper-depleted media or cell lysates for biological studies, PSP-immobilized ligands might prove equally useful for applications in radiochemistry, materials science, and environmental science.
Collapse
Affiliation(s)
- Arielle Nabatilan
- School of Chemistry and Biochemistry and Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, 901 Atlantic Drive, Atlanta, GA, 30332, USA
| | - M Thomas Morgan
- School of Chemistry and Biochemistry and Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, 901 Atlantic Drive, Atlanta, GA, 30332, USA
| | - Sara Netzer
- School of Chemistry and Biochemistry and Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, 901 Atlantic Drive, Atlanta, GA, 30332, USA
| | - Christoph J Fahrni
- School of Chemistry and Biochemistry and Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, 901 Atlantic Drive, Atlanta, GA, 30332, USA.
| |
Collapse
|
3
|
Saini S, Bartels JL, Appiah JPK, Rider JH, Baumhover N, Schultz MK, Lapi SE. Optimized Methods for the Production of High-Purity 203Pb Using Electroplated Thallium Targets. J Nucl Med 2023; 64:1791-1797. [PMID: 37652545 DOI: 10.2967/jnumed.123.265976] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2023] [Revised: 07/17/2023] [Indexed: 09/02/2023] Open
Abstract
203Pb is a surrogate imaging match for 212Pb. This elementally matched pair is emerging as a suitable pair for imaging and targeted radionuclide therapy in cancer care. Because of the half-life (51.9 h) and low-energy γ-rays emitted, 203Pb is suitable for the development of diagnostic radiopharmaceuticals. The aim of this work was to optimize the production and separation of high-specific-activity 203Pb using electroplated thallium targets. We further investigated the radiochemistry optimization using a suitable chelator, tetraazacyclododecane-1,4,7-triacetic acid (DO3A), and targeting vector, VMT-α-NET (lead-specific chelator conjugated to tyr3-octreotide via a polyethylene glycol linker). Methods: Targets were prepared by electroplating of natural or enriched (205Tl) thallium metal. Scanning electron microscopy was performed to determine the structure and elemental composition of electroplated targets. Targets were irradiated with 24-MeV protons with varying current and beam time to investigate target durability. 203Pb was purified from the thallium target material using an extraction resin (lead resin) column followed by a second column using a weak cation-exchange resin to elute the lead isotope as [203Pb]PbCl2 Inductively coupled plasma mass spectrometry studies were used to further characterize the separation for trace metal contaminants. Radiolabeling efficiency was also investigated for DO3A chelator and VMT-α-NET (a peptide-based targeting conjugate). Results: Electroplated targets were prepared at a high plating density of 76-114 mg/cm2 using a plating time of 5 h. A reproducible separation method was established with a final elution in HCl (400 μL, 1 M) suitable for radiolabeling. Greater than 90% recovery yields were achieved, with an average specific activity of 37.7 ± 5.4 GBq/μmol (1.1 ± 0.1 Ci/μmol). Conclusion: An efficient electroplating method was developed to prepare thallium targets suitable for cyclotron irradiation. A simple and fast separation method was developed for routine 203Pb production with high recovery yields and purity.
Collapse
Affiliation(s)
- Shefali Saini
- Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama; and
| | - Jennifer L Bartels
- Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama; and
| | - Jean-Pierre K Appiah
- Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama; and
| | - Jason H Rider
- Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama; and
| | | | | | - Suzanne E Lapi
- Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama; and
| |
Collapse
|
4
|
Hussain M, Qaim SM, Spahn I, Aslam MN, Neumaier B. Copper radionuclides for theranostic applications: towards standardisation of their nuclear data. A mini-review. Front Chem 2023; 11:1270351. [PMID: 37841203 PMCID: PMC10570421 DOI: 10.3389/fchem.2023.1270351] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Accepted: 09/08/2023] [Indexed: 10/17/2023] Open
Abstract
Copper has several clinically relevant radioisotopes and versatile coordination chemistry, allowing attachment of its radionuclides to biological molecules. This characteristic makes it suitable for applications in molecular imaging or radionuclide targeted therapy. Of particular interest in nuclear medicine today is the theranostic approach. This brief review considers five radionuclides of copper. These are Cu-60, Cu-61, Cu-62, Cu-64, and Cu-67. The first four are positron emitters for imaging, and the last one Cu-67 is a β--emitting radionuclide suitable for targeted therapy. The emphasis here is on theory-aided evaluation of available experimental data with a view to establishing standardised cross-section database for production of the relevant radionuclide in high purity. Evaluated cross section data of the positron emitters have been already extensively reported; so here they are only briefly reviewed. More attention is given to the data of the 68Zn(p,2p)67Cu intermediate energy reaction which is rather commonly used for production of 67Cu.
Collapse
Affiliation(s)
- Mazhar Hussain
- Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich (FZJ), Jülich, Germany
- Department of Physics, Government College University Lahore (GCUL), Lahore, Pakistan
| | - Syed M. Qaim
- Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich (FZJ), Jülich, Germany
| | - Ingo Spahn
- Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich (FZJ), Jülich, Germany
| | - M. Naveed Aslam
- Department of Physics, COMSATS University Islamabad, Lahore, Pakistan
| | - Bernd Neumaier
- Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich (FZJ), Jülich, Germany
| |
Collapse
|
5
|
Serban RM, Niculae D, Manda G, Neagoe I, Dobre M, Niculae DA, Temelie M, Mustăciosu C, Leonte RA, Chilug LE, Cornoiu MR, Cocioabă D, Stan M, Dinischiotu A. Modifications in cellular viability, DNA damage and stress responses inflicted in cancer cells by copper-64 ions. Front Med (Lausanne) 2023; 10:1197846. [PMID: 37415761 PMCID: PMC10320858 DOI: 10.3389/fmed.2023.1197846] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Accepted: 05/31/2023] [Indexed: 07/08/2023] Open
Abstract
Due to combined therapeutical emissions, a high linear energy transfer Auger-electrons with the longer ranged β- particles, 64Cu-based radiopharmaceuticals raise particular theragnostic interest in cancer, by joined therapeutic and real-time PET imaging properties. The in vitro study aimed to investigate the biological and molecular background of 64CuCl2 therapy by analyzing the damages and stress responses inflicted in various human normal and tumor cell lines. Colon (HT29 and HCT116) and prostate carcinoma (DU145) cell lines, as well as human normal BJ fibroblasts, were treated up to 72 h with 2-40 MBq/mL 64CuCl2. Radioisotope uptake and retention were assessed, and cell viability/death, DNA damage, oxidative stress, and the expression of 84 stress genes were investigated at various time points after [64Cu]CuCl2 addition. All the investigated cells incorporated 64Cu ions similarly, independent of their tumoral or normal status, but their fate after exposure to [64Cu]CuCl2 was cell-dependent. The most striking cytotoxic effects of the radioisotope were registered in colon carcinoma HCT116 cells, for which a substantial decrease in the number of metabolically active cells, and an increased DNA damage and oxidative stress were registered. The stress gene expression study highlighted the activation of both death and repair mechanisms in these cells, related to extrinsic apoptosis, necrosis/necroptosis or autophagy, and cell cycle arrest, nucleotide excision repair, antioxidant, and hypoxic responses, respectively. The in vitro study indicated that 40 MBq/mL [64Cu]CuCl2 delivers a therapeutic effect in human colon carcinoma, but its use is limited by harmful, yet lower effects on normal fibroblasts. The exposure of tumor cells to 20 MBq/mL [64Cu]CuCl2, might be used for a softer approach aiming for a lower radiotoxicity in normal fibroblasts as compared to tumor cells. This radioactive concentration was able to induce a persistent decrease in the number of metabolically active cells, accompanied by DNA damage and oxidative stress, associated with significant changes in stress gene expression in HCT116 colon cancer cells.
Collapse
Affiliation(s)
- Radu M. Serban
- Radiopharmaceutical Research Centre, Horia Hulubei National Institute for Physics and Nuclear Engineering (IFIN-HH), Măgurele, Ilfov, Romania
- Faculty of Biology, University of Bucharest, Bucharest, Romania
| | - Dana Niculae
- Radiopharmaceutical Research Centre, Horia Hulubei National Institute for Physics and Nuclear Engineering (IFIN-HH), Măgurele, Ilfov, Romania
- Faculty of Pharmacy, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania
| | - Gina Manda
- Radiobiology Laboratory, National Institute of Pathology "Victor Babeș", Bucharest, Romania
| | - Ionela Neagoe
- Radiobiology Laboratory, National Institute of Pathology "Victor Babeș", Bucharest, Romania
| | - Maria Dobre
- Radiobiology Laboratory, National Institute of Pathology "Victor Babeș", Bucharest, Romania
| | - Dragoș A. Niculae
- Faculty of Pharmacy, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania
| | - Mihaela Temelie
- Radiopharmaceutical Research Centre, Horia Hulubei National Institute for Physics and Nuclear Engineering (IFIN-HH), Măgurele, Ilfov, Romania
| | - Cosmin Mustăciosu
- Radiopharmaceutical Research Centre, Horia Hulubei National Institute for Physics and Nuclear Engineering (IFIN-HH), Măgurele, Ilfov, Romania
| | - Radu A. Leonte
- Radiopharmaceutical Research Centre, Horia Hulubei National Institute for Physics and Nuclear Engineering (IFIN-HH), Măgurele, Ilfov, Romania
| | - Livia E. Chilug
- Radiopharmaceutical Research Centre, Horia Hulubei National Institute for Physics and Nuclear Engineering (IFIN-HH), Măgurele, Ilfov, Romania
| | - Maria R. Cornoiu
- Radiopharmaceutical Research Centre, Horia Hulubei National Institute for Physics and Nuclear Engineering (IFIN-HH), Măgurele, Ilfov, Romania
- Doctoral School of Applied Chemistry and Materials Science, Faculty of Chemical Engineering and Biotechnologies, University Politehnica of Bucharest, Bucharest, Romania
| | - Diana Cocioabă
- Radiopharmaceutical Research Centre, Horia Hulubei National Institute for Physics and Nuclear Engineering (IFIN-HH), Măgurele, Ilfov, Romania
- Doctoral School of Physics, Faculty of Physics, University of Bucharest, Măgurele, Ilfov, Romania
| | - Miruna Stan
- Faculty of Biology, University of Bucharest, Bucharest, Romania
| | | |
Collapse
|
6
|
Brühlmann SA, Walther M, Kreller M, Reissig F, Pietzsch HJ, Kniess T, Kopka K. Cyclotron-Based Production of 67Cu for Radionuclide Theranostics via the 70Zn(p,α) 67Cu Reaction. Pharmaceuticals (Basel) 2023; 16:314. [PMID: 37259458 PMCID: PMC9961624 DOI: 10.3390/ph16020314] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2023] [Revised: 02/13/2023] [Accepted: 02/14/2023] [Indexed: 10/28/2023] Open
Abstract
Theranostic matched pairs of radionuclides have aroused interest during the last couple of years, and in that sense, copper is one element that has a lot to offer, and although 61Cu and 64Cu are slowly being established as diagnostic radionuclides for PET, the availability of the therapeutic counterpart 67Cu plays a key role for further radiopharmaceutical development in the future. Until now, the 67Cu shortage has not been solved; however, different production routes are being explored. This project aims at the production of no-carrier-added 67Cu with high radionuclidic purity with a medical 30MeV compact cyclotron via the 70Zn(p,α)67Cu reaction. With this purpose, proton irradiation of electrodeposited 70Zn targets was performed followed by two-step radiochemical separation based on solid-phase extraction. Activities of up to 600MBq 67Cu at end of bombardment, with radionuclidic purities over 99.5% and apparent molar activities of up to 80MBq/nmol, were quantified.
Collapse
Affiliation(s)
- Santiago Andrés Brühlmann
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany
- School of Science, Faculty of Chemistry and Food Chemistry, Technische Universität Dresden, Bergstraße 66, 01069 Dresden, Germany
| | - Martin Walther
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany
| | - Martin Kreller
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany
| | - Falco Reissig
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany
| | - Hans-Jürgen Pietzsch
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany
| | - Torsten Kniess
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany
| | - Klaus Kopka
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany
- School of Science, Faculty of Chemistry and Food Chemistry, Technische Universität Dresden, Bergstraße 66, 01069 Dresden, Germany
- National Center for Tumor Diseases (NCT) Dresden, University Hospital Carl Gustav Carus, Fetscherstraße 74, 01307 Dresden, Germany
- German Cancer Consortium (DKTK), Partner Site Dresden, Fetscherstraße 74, 01307 Dresden, Germany
| |
Collapse
|
7
|
Encapsulation of 67Cu therapeutic radiometal in luminescent lanthanide phosphate core and core-shell nanoparticles. Appl Radiat Isot 2022; 186:110296. [DOI: 10.1016/j.apradiso.2022.110296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2021] [Revised: 05/06/2022] [Accepted: 05/13/2022] [Indexed: 11/18/2022]
|
8
|
Qaim SM, Spahn I, Scholten B, Spellerberg S, Neumaier B. The role of chemistry in accelerator-based production and separation of radionuclides as basis for radiolabelled compounds for medical applications. RADIOCHIM ACTA 2022. [DOI: 10.1515/ract-2022-0017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
Radiochemical separations used in large scale routine production of diagnostic and therapeutic radionuclides at a particle accelerator for patient care are briefly outlined. The role of chemistry at various stages of development of a production route of a novel radionuclide, namely nuclear data measurement, high-current targetry, chemical processing and quality control of the product, is discussed in detail. Special attention is paid to production of non-standard positron emitters (e.g. 44gSc, 64Cu, 68Ga, etc.) at a cyclotron and novel therapeutic radionuclides (e.g. 67Cu, 225Ac, etc.) at an accelerator. Some typical examples of radiochemical methods involved are presented.
Collapse
Affiliation(s)
- Syed M. Qaim
- Institut für Neurowissenschaften und Medizin: INM-5 (Nuklearchemie), Forschungszentrum Jülich GmbH , D-52425 Jülich , Germany
| | - Ingo Spahn
- Institut für Neurowissenschaften und Medizin: INM-5 (Nuklearchemie), Forschungszentrum Jülich GmbH , D-52425 Jülich , Germany
| | - Bernhard Scholten
- Institut für Neurowissenschaften und Medizin: INM-5 (Nuklearchemie), Forschungszentrum Jülich GmbH , D-52425 Jülich , Germany
| | - Stefan Spellerberg
- Institut für Neurowissenschaften und Medizin: INM-5 (Nuklearchemie), Forschungszentrum Jülich GmbH , D-52425 Jülich , Germany
| | - Bernd Neumaier
- Institut für Neurowissenschaften und Medizin: INM-5 (Nuklearchemie), Forschungszentrum Jülich GmbH , D-52425 Jülich , Germany
| |
Collapse
|
9
|
De Nardo L, Pupillo G, Mou L, Esposito J, Rosato A, Meléndez‐Alafort L. A feasibility study of the therapeutic application of a mixture of 67/64 Cu radioisotopes produced by cyclotrons with proton irradiation. Med Phys 2022; 49:2709-2724. [PMID: 35134261 PMCID: PMC9305914 DOI: 10.1002/mp.15524] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2021] [Revised: 01/21/2022] [Accepted: 01/29/2022] [Indexed: 11/26/2022] Open
Abstract
PURPOSE 64 Cu and 67 Cu radioisotopes have nuclear characteristics suitable for nuclear medicine applications. The production of 64 Cu is already well established. However, the production of 67 Cu in quantities suitable to conduct clinical trials is more challenging as it leads to the coproduction of other Cu isotopes, in particular 64 Cu. The aim of this study is to investigate the possibility of using a CuCl2 solution with a mixture of 67/64 Cu radioisotopes for therapeutic purposes, providing an alternative solution for the cyclotron production problem. METHODS Copper radioisotopes activities were calculated by considering proton beam irradiation of the following targets: (i) 70 Zn in the energy range 70-45 MeV; (ii) 68 Zn in the energy range 70-35 MeV; (iii) a combination of 70 Zn (70-55 MeV) and 68 Zn (55-35 MeV). The contribution of each copper radioisotope to the human-absorbed dose was estimated with OLINDA/EXM software using the biokinetic model for CuCl2 published by ICRP 53. The total absorbed dose generated by the 67/64 CuCl2 mixture, obtained through different production routes, was calculated at different times after the end of the bombardment (EOB). A simple spherical model was used to simulate tumors of different sizes containing uniformly distributed 67/64 Cu mixture and to calculate the absorbed dose of self-irradiation. The biological damage produced by 67 Cu and 64 Cu was also evaluated through cellular dosimetry and cell surviving fraction assessment using the MIRDcell code, considering two prostate cancer cell lines with different radiosensitivity. RESULTS The absorbed dose to healthy organs and the effective dose (ED) per unit of administered activity of 67 CuCl2 are higher than those of 64 CuCl2 . Absorbed dose values per unit of administered activity of 67/64 CuCl2 mixture increase with time after the EOB because the amount of 67 Cu in the mixture increases. Survival data showed that the biological damage caused per each decay of 67 Cu is greater than that of 64 Cu, assuming that radionuclides remain accumulated in the cell cytoplasm. Sphere model calculations demonstrated that 64 Cu administered activity must be about five times higher than that of 67 Cu to obtain the same absorbed dose for tumor mass between 0.01 and 10 g and about 10 times higher for very small spheres. Consequently, the 64 CuCl2 -absorbed dose to healthy organs will reach higher values than those of 67 CuCl2 . The supplemental activity of the 67/64 CuCl2 mixture, required to get the same tumor-absorbed dose produced by 67 CuCl2 , triggers a dose increment (DI) in healthy organs. The waiting time post-EOB necessary to keep this DI below 10% (t10% ) depends on the irradiation methods employed for the production of the 67/64 CuCl2 mixture. CONCLUSIONS A mixture of cyclotron produced 67/64 Cu radioisotopes proved to be an alternative solution for the therapeutic use of CuCl2 with minimal DI to healthy organs compared with pure 67 Cu. Irradiation of a 70 Zn+68 Zn target in the 70-35 MeV proton energy range for 185 h appears to be the best option from among all the production routes investigated, as it gives the maximum amount of activity, the shortest t10% (10 h), and less than 1% of 61 Cu and 60 Cu impurities.
Collapse
Affiliation(s)
- Laura De Nardo
- Department of Physics and AstronomyUniversity of PaduaVia Marzolo 8Padova35131Italy
- INFN‐PadovaNational Institute of Nuclear PhysicsVia Marzolo 8Padova35131Italy
| | - Gaia Pupillo
- INFN‐Legnaro National LaboratoriesNational Institute of Nuclear PhysicsViale dell'Università 2Legnaro35020Italy
| | - Liliana Mou
- INFN‐Legnaro National LaboratoriesNational Institute of Nuclear PhysicsViale dell'Università 2Legnaro35020Italy
| | - Juan Esposito
- INFN‐Legnaro National LaboratoriesNational Institute of Nuclear PhysicsViale dell'Università 2Legnaro35020Italy
| | - Antonio Rosato
- Department of SurgeryOncology and GastroenterologyUniversity of PaduaPadovaItaly
- Veneto Institute of Oncology IOV‐IRCCSVia Gattamelata 64Padova35138Italy
| | | |
Collapse
|
10
|
Mou L, Martini P, Pupillo G, Cieszykowska I, Cutler CS, Mikołajczak R. 67Cu Production Capabilities: A Mini Review. MOLECULES (BASEL, SWITZERLAND) 2022; 27:molecules27051501. [PMID: 35268600 PMCID: PMC8912090 DOI: 10.3390/molecules27051501] [Citation(s) in RCA: 23] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 02/15/2022] [Accepted: 02/18/2022] [Indexed: 01/09/2023]
Abstract
Is the 67Cu production worldwide feasible for expanding preclinical and clinical studies? How can we face the ingrowing demands of this emerging and promising theranostic radionuclide for personalized therapies? This review looks at the different production routes, including the accelerator- and reactor-based ones, providing a comprehensive overview of the actual 67Cu supply, with brief insight into its use in non-clinical and clinical studies. In addition to the most often explored nuclear reactions, this work focuses on the 67Cu separation and purification techniques, as well as the target material recovery procedures that are mandatory for the economic sustainability of the production cycle. The quality aspects, such as radiochemical, chemical, and radionuclidic purity, with particular attention to the coproduction of the counterpart 64Cu, are also taken into account, with detailed comparisons among the different production routes. Future possibilities related to new infrastructures are included in this work, as well as new developments on the radiopharmaceuticals aspects.
Collapse
Affiliation(s)
- Liliana Mou
- Legnaro National Laboratories, National Institute for Nuclear Physics, Legnaro, 35020 Padova, Italy; (L.M.); (G.P.)
| | - Petra Martini
- Department of Environmental and Prevention Sciences, University of Ferrara, 44121 Ferrara, Italy; or
| | - Gaia Pupillo
- Legnaro National Laboratories, National Institute for Nuclear Physics, Legnaro, 35020 Padova, Italy; (L.M.); (G.P.)
| | - Izabela Cieszykowska
- National Centre for Nuclear Research, Radioisotope Centre POLATOM, 05-400 Otwock, Poland;
| | - Cathy S. Cutler
- Brookhaven National Laboratory, Collider Accelerator Department, Upton, NY 11973, USA;
| | - Renata Mikołajczak
- National Centre for Nuclear Research, Radioisotope Centre POLATOM, 05-400 Otwock, Poland;
- Correspondence:
| |
Collapse
|
11
|
Fan FL, Li HW, Cheng NW, Huang QG, Chen DS, Wu XL, Qin Z. Selective adsorption and separation of Cu(II) from Zn solution by CU resin. J Radioanal Nucl Chem 2022. [DOI: 10.1007/s10967-022-08191-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
12
|
van der Meulen NP, Talip Z. Non-conventional radionuclides: The pursuit for perfection. Nucl Med Mol Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00052-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
13
|
Copper Isotopes in Theranostics. Nucl Med Mol Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00073-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
14
|
Large scale production of 64Cu and 67Cu via the 64Zn(n, p)64Cu and 68Zn(n, np/d)67Cu reactions using accelerator neutrons. J Radioanal Nucl Chem 2021. [DOI: 10.1007/s10967-021-07987-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
15
|
George KJH, Borjian S, Cross MC, Hicks JW, Schaffer P, Kovacs MS. Expanding the PET radioisotope universe utilizing solid targets on small medical cyclotrons. RSC Adv 2021; 11:31098-31123. [PMID: 35498914 PMCID: PMC9041346 DOI: 10.1039/d1ra04480j] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2021] [Accepted: 08/25/2021] [Indexed: 12/17/2022] Open
Abstract
Molecular imaging with medical radioisotopes enables the minimally-invasive monitoring of aberrant biochemical, cellular and tissue-level processes in living subjects. The approach requires the administration of radiotracers composed of radioisotopes attached to bioactive molecules, the pairing of which considers several aspects of the radioisotope in addition to the biological behavior of the targeting molecule to which it is attached. With the advent of modern cellular and biochemical techniques, there has been a virtual explosion in potential disease recognition antigens as well as targeting moieties, which has subsequently opened new applications for a host of emerging radioisotopes with well-matched properties. Additionally, the global radioisotope production landscape has changed rapidly, with reactor-based production and its long-defined, large-scale centralized manufacturing and distribution paradigm shifting to include the manufacture and distribution of many radioisotopes via a worldwide fleet of cyclotrons now in operation. Cyclotron-based radioisotope production has become more prevalent given the commercial availability of instruments, coupled with the introduction of new target hardware, process automation and target manufacturing methods. These advances enable sustained, higher-power irradiation of solid targets that allow hospital-based radiopharmacies to produce a suite of radioisotopes that drive research, clinical trials, and ultimately clinical care. Over the years, several different radioisotopes have been investigated and/or selected for radiolabeling due to favorable decay characteristics (i.e. a suitable half-life, high probability of positron decay, etc.), well-elucidated chemistry, and a feasible production framework. However, longer-lived radioisotopes have surged in popularity given recent regulatory approvals and incorporation of radiopharmaceuticals into patient management within the medical community. This review focuses on the applications, nuclear properties, and production and purification methods for some of the most frequently used/emerging positron-emitting, solid-target-produced radioisotopes that can be manufactured using small-to-medium size cyclotrons (≤24 MeV).
Collapse
Affiliation(s)
- K J H George
- Lawson Health Research Institute 268 Grosvenor Street London ON N6A 4V2 Canada
- Medical Biophysics, Western University 1151 Richmond Street N. London ON N6A 5C1 Canada
| | - S Borjian
- ARTMS 301-4475 Wayburn Drive Burnaby BC V5G 4X4 Canada
| | - M C Cross
- ARTMS 301-4475 Wayburn Drive Burnaby BC V5G 4X4 Canada
| | - J W Hicks
- Lawson Health Research Institute 268 Grosvenor Street London ON N6A 4V2 Canada
- Medical Biophysics, Western University 1151 Richmond Street N. London ON N6A 5C1 Canada
| | - P Schaffer
- Life Sciences, TRIUMF 4004 Wesbrook Mall Vancouver BC V6T 2A3 Canada
- ARTMS 301-4475 Wayburn Drive Burnaby BC V5G 4X4 Canada
- Radiology, University of British Columbia 2775 Laurel St Vancouver BC V5Z 1M9 Canada
- Chemistry, Simon Fraser University 8888 University Dr Burnaby BC V5A 1S6 Canada
| | - M S Kovacs
- Lawson Health Research Institute 268 Grosvenor Street London ON N6A 4V2 Canada
- Medical Biophysics, Western University 1151 Richmond Street N. London ON N6A 5C1 Canada
- Medical Imaging, Western University 1151 Richmond Street N. London ON N6A 5C1 Canada
| |
Collapse
|
16
|
Herrero Álvarez N, Bauer D, Hernández-Gil J, Lewis JS. Recent Advances in Radiometals for Combined Imaging and Therapy in Cancer. ChemMedChem 2021; 16:2909-2941. [PMID: 33792195 DOI: 10.1002/cmdc.202100135] [Citation(s) in RCA: 36] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2021] [Indexed: 12/14/2022]
Abstract
Nuclear medicine is defined as the use of radionuclides for diagnostic and therapeutic applications. The imaging modalities positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are based on γ-emissions of specific energies. The therapeutic technologies are based on β- -particle-, α-particle-, and Auger electron emitters. In oncology, PET and SPECT are used to detect cancer lesions, to determine dosimetry, and to monitor therapy effectiveness. In contrast, radiotherapy is designed to irreparably damage tumor cells in order to eradicate or control the disease's progression. Radiometals are being explored for the development of diagnostic and therapeutic radiopharmaceuticals. Strategies that combine both modalities (diagnostic and therapeutic), referred to as theranostics, are promising candidates for clinical applications. This review provides an overview of the basic concepts behind therapeutic and diagnostic radiopharmaceuticals and their significance in contemporary oncology. Select radiometals that significantly impact current and upcoming cancer treatment strategies are grouped as clinically suitable theranostics pairs. The most important physical and chemical properties are discussed. Standard production methods and current radionuclide availability are provided to indicate whether a cost-efficient use in a clinical routine is feasible. Recent preclinical and clinical developments and outline perspectives for the radiometals are highlighted in each section.
Collapse
Affiliation(s)
- Natalia Herrero Álvarez
- Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - David Bauer
- Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Javier Hernández-Gil
- Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.,Biomedical MRI/MoSAIC, Department of Imaging and Pathology, Katholieke Universiteit, Herestraat 49, 3000, Leuven, Belgium
| | - Jason S Lewis
- Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.,Department of Radiology, Weill Cornell Medical College, 1300 York Avenue, New York, NY, 10065, USA.,Department of Pharmacology, Weill-Cornell Medical College, New York, NY, 10065, USA
| |
Collapse
|
17
|
Hao G, Mastren T, Silvers W, Hassan G, Öz OK, Sun X. Copper-67 radioimmunotheranostics for simultaneous immunotherapy and immuno-SPECT. Sci Rep 2021; 11:3622. [PMID: 33574346 PMCID: PMC7878802 DOI: 10.1038/s41598-021-82812-1] [Citation(s) in RCA: 32] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2020] [Accepted: 01/22/2021] [Indexed: 02/01/2023] Open
Abstract
Copper-67 (t1/2 = 2.58 days) decays by β- ([Formula: see text]: 562 keV) and γ-rays (93 keV and 185 keV) rendering it with potential for both radionuclide therapy and single-photon emission computed tomography (SPECT) imaging. Prompted by the recent breakthrough of 67Cu production with high specific activity, high radionuclidic purity, and sufficient quantities, the interest in the theranostic potential of 67Cu has been rekindled. This work addresses the practicability of developing 67Cu-labeled antibodies with substantially improved quality for cancer radioimmunotheranostics. Proof of concept is demonstrated with pertuzumab, a US-FDA-approved monoclonal antibody for combination therapies of HER2-positive breast cancer. With an average number of 1.9 chelators coupled to each antibody, we achieved a two-order of magnitude increase in radiolabeling efficiency compared to literature reports. In a preclinical therapeutic study, mice (n = 4-7/group) bearing HER2+ xenografts exhibited a 67Cu-dose dependent tumor-growth inhibition from 67Cu-labeled-Pertuzumab co-administered with trastuzumab. Furthermore, greater tumor size reduction was observed with 67Cu-labeled-pertuzumab formulations of higher specific activity. The potential of SPECT imaging with 67Cu radiopharmaceuticals was tested after 67Cu-labeled-Pertuzumab administration. Impressively, all tumors were clearly visualized by SPECT imaging with 67Cu-labeled-Pertuzumab even at day 5 post injection. This work demonstrates it is practical to use 67Cu radioimmunoconjugates for cancer radioimmunotheranostics.
Collapse
Affiliation(s)
- Guiyang Hao
- Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA
| | - Tara Mastren
- Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA
| | - William Silvers
- Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA
| | - Gedaa Hassan
- Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA
| | - Orhan K Öz
- Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA
| | - Xiankai Sun
- Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
- Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
| |
Collapse
|
18
|
Yang H, Gao F, McNeil B, Zhang C, Yuan Z, Zeisler S, Kumlin J, Zeisler J, Bénard F, Ramogida C, Schaffer P. Synthesis of DOTA-pyridine chelates for 64Cu coordination and radiolabeling of αMSH peptide. EJNMMI Radiopharm Chem 2021; 6:3. [PMID: 33438075 PMCID: PMC7803858 DOI: 10.1186/s41181-020-00119-4] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2020] [Accepted: 12/26/2020] [Indexed: 12/02/2022] Open
Abstract
Background 64Cu is one of the few radioisotopes that can be used for both imaging and therapy, enabling theranostics with identical chemical composition. Development of stable chelators is essential to harness the potential of this isotope, challenged by the presence of endogenous copper chelators. Pyridyl type chelators show good coordination ability with copper, prompting the present study of a series of chelates DOTA-xPy (x = 1–4) that sequentially substitute carboxyl moieties with pyridyl moieties on a DOTA backbone. Results We found that the presence of pyridyl groups significantly increases 64Cu labeling conversion yield, with DOTA-2Py, −3Py and -4Py quantitatively complexing 64Cu at room temperature within 5 min (1 × 10− 4 M). [64Cu]Cu-DOTA-xPy (x = 2–4) exhibited good stability in human serum up to 24 h. When challenged with 1000 eq. of NOTA, no transmetallation was observed for all three 64Cu complexes. DOTA-xPy (x = 1–3) were conjugated to a cyclized α-melanocyte-stimulating hormone (αMSH) peptide by using one of the pendant carboxyl groups as a bifunctional handle. [64Cu]Cu-DOTA-xPy-αMSH retained good serum stability (> 96% in 24 h) and showed high binding affinity (Ki = 2.1–3.7 nM) towards the melanocortin 1 receptor. Conclusion DOTA-xPy (x = 1–3) are promising chelators for 64Cu. Further in vivo evaluation is necessary to assess the full potential of these chelators as a tool to enable further theranostic radiopharmaceutical development. Supplementary Information The online version contains supplementary material available at 10.1186/s41181-020-00119-4.
Collapse
Affiliation(s)
- Hua Yang
- Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC, V6T 2A3, Canada
| | - Feng Gao
- Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC, V6T 2A3, Canada
| | - Brooke McNeil
- Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC, V6T 2A3, Canada.,Department of Chemistry, Simon Fraser University, 8888 University Dr, Burnaby, BC, V5A 1S6, Canada
| | - Chengcheng Zhang
- Department of Molecular Oncology, BC Cancer Research Centre, 675 West 10th Ave, Vancouver, BC, V5Z 1L3, Canada
| | - Zheliang Yuan
- Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC, V6T 2A3, Canada
| | - Stefan Zeisler
- Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC, V6T 2A3, Canada
| | - Joel Kumlin
- Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC, V6T 2A3, Canada
| | - Jutta Zeisler
- Department of Molecular Oncology, BC Cancer Research Centre, 675 West 10th Ave, Vancouver, BC, V5Z 1L3, Canada
| | - François Bénard
- Department of Molecular Oncology, BC Cancer Research Centre, 675 West 10th Ave, Vancouver, BC, V5Z 1L3, Canada.,Department of Radiology, University of British Columbia, 2775 Laurel St, Vancouver, BC, V5Z 1M9, Canada
| | - Caterina Ramogida
- Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC, V6T 2A3, Canada.,Department of Chemistry, Simon Fraser University, 8888 University Dr, Burnaby, BC, V5A 1S6, Canada
| | - Paul Schaffer
- Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC, V6T 2A3, Canada. .,Department of Chemistry, Simon Fraser University, 8888 University Dr, Burnaby, BC, V5A 1S6, Canada. .,Department of Radiology, University of British Columbia, 2775 Laurel St, Vancouver, BC, V5Z 1M9, Canada.
| |
Collapse
|
19
|
NAGAI Y. Production scheme for diagnostic-therapeutic radioisotopes by accelerator neutrons. PROCEEDINGS OF THE JAPAN ACADEMY. SERIES B, PHYSICAL AND BIOLOGICAL SCIENCES 2021; 97:292-323. [PMID: 34121042 PMCID: PMC8403527 DOI: 10.2183/pjab.97.017] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/14/2020] [Accepted: 03/19/2021] [Indexed: 06/12/2023]
Abstract
Interest has been growing in the development of medical radioisotopes used for noninvasive nuclear medicine imaging of disease and cancer therapy. Especially the development of an alternative production scheme of 99Mo, the mother radioisotope of 99mTc used for imaging, is required, because the current supply chain of the reactor product 99Mo is fragile worldwide. We have proposed a new production scheme of 99Mo as well as therapeutic radioisotopes, such as 64Cu and 67Cu, using accelerator neutrons provided by the natC(d,n) reaction. Based on this scheme we have obtained high-quality 99mTc, 64Cu, and 67Cu suitable for clinical use by developing both production and separation methods of the radioisotopes. We proposed a new facility to constantly and reliably produce a wide variety of high-quality, carrier-free radioisotopes, including 99Mo, with accelerator neutrons. We report on the development of the proposed scheme and future prospects of the facility toward the domestic production of medical radioisotopes.
Collapse
Affiliation(s)
- Yasuki NAGAI
- Professor Emeritus, Osaka University, Suita, Osaka, Japan
- Professor Emeritus, Tokyo Institute of Technology, Tokyo, Japan
- QST-Associate, National Institute for Quantum and Radiological Science and Technology, Tokai, Ibaraki, Japan
- Research Professor, Tohoku University, Sendai, Miyagi, Japan
- Research Fellow, Chiyoda Technol Co., Tokyo, Japan
| |
Collapse
|
20
|
Abstract
Over the past decade, theranostic imaging has emerged as a powerful clinical tool in oncology for identifying patients likely to respond to targeted therapies and for monitoring the response of patients to treatment. Herein, we report a theranostic approach to pretargeted radioimmunotherapy (PRIT) based on a pair of radioisotopes of copper: positron-emitting copper-64 (64Cu, t 1/2 = 12.7 h) and beta particle-emitting copper-67 (67Cu, t 1/2 = 61.8 h). This strategy is predicated on the in vivo ligation between a trans-cyclooctene (TCO)-bearing antibody and a tetrazine (Tz)-based radioligand via the rapid and bioorthogonal inverse electron-demand Diels-Alder reaction. Longitudinal therapy studies were conducted in a murine model of human colorectal carcinoma using an immunoconjugate of the huA33 antibody modified with TCO (huA33-TCO) and a 67Cu-labeled Tz radioligand ([67Cu]Cu-MeCOSar-Tz). The injection of huA33-TCO followed 72 h later by the administration of 18.5, 37.0, or 55.5 MBq of [67Cu]Cu-MeCOSar-Tz produced a dose-dependent therapeutic response, with the median survival time increasing from 68 d for the lowest dose to >200 d for the highest. Furthermore, we observed that mice that received the highest dose of [67Cu]Cu-MeCOSar-Tz in a fractionated manner exhibited improved hematological values without sacrificing therapeutic efficacy. Dual radionuclide experiments in which a single administration of huA33-TCO was followed by separate injections of [64Cu]Cu-MeCOSar-Tz and [67Cu]Cu-MeCOSar-Tz revealed that the positron emission tomography images produced by the former accurately predicted the efficacy of the latter. In these experiments, a correlation was observed between the tumoral uptake of [64Cu]Cu-MeCOSar-Tz and the subsequent therapeutic response to [67Cu]Cu-MeCOSar-Tz.
Collapse
|
21
|
Maschmeyer RT, Gholami YH, Kuncic Z. Clustering effects in nanoparticle-enhanced β − emitting internal radionuclide therapy: a Monte Carlo study. Phys Med Biol 2020; 65:125007. [DOI: 10.1088/1361-6560/ab8079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
22
|
Kelly JM, Ponnala S, Amor-Coarasa A, Zia NA, Nikolopoulou A, Williams C, Schlyer DJ, DiMagno SG, Donnelly PS, Babich JW. Preclinical Evaluation of a High-Affinity Sarcophagine-Containing PSMA Ligand for 64Cu/ 67Cu-Based Theranostics in Prostate Cancer. Mol Pharm 2020; 17:1954-1962. [PMID: 32286841 DOI: 10.1021/acs.molpharmaceut.0c00060] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
The application of small molecules targeting prostate-specific membrane antigen (PSMA) has emerged as a highly promising clinical strategy for visualization and treatment of prostate cancer. Ligands that integrate the ability to both quantify the distribution of radioactivity and treat disease through the use of a matched pair of radionuclides have particular value in clinical and regulatory settings. In this study, we describe the development and preclinical evaluation of RPS-085, a ligand that binds PSMA and serum albumin and exploits the 64/67Cu radionuclide pair for prostate cancer theranostics. RPS-085 was synthesized by conjugation of a PSMA-targeting moiety, an Nε-(2-(4-iodophenyl)acetyl)lysine albumin binding group, and a bifunctionalized MeCOSar chelator. The IC50 of the metal-free RPS-085 was determined in a competitive binding assay. The affinity for human serum albumin of the radiolabeled compound was determined by high-performance affinity chromatography. Radiolabeling was performed in NH4OAc buffer at 25 °C. The stability of the radiolabeled compounds was assessed in vitro and in vivo. The biodistribution of [64/67Cu]Cu-RPS-085 was determined following intravenous administration to male BALB/c mice bearing LNCaP tumor xenografts. The radiochemical yields of [64/67Cu]Cu-RPS-085 were nearly quantitative after 20 min. The metal-free complex is a potent inhibitor of PSMA (IC50 = 29 ± 2 nM), and the radiolabeled compound has moderate affinity for human serum albumin (Kd = 9.9 ± 1.7 μM). Accumulation of the tracer in mice was primarily evident in tumor and kidneys. Activity in all other tissues, including blood, was negligible, and the radiolabeled compounds demonstrated high stability in vitro and in vivo. Tumor activity reached a maximum at 4 h post injection (p.i.) and cleared gradually over a period of 96 h. By contrast, activity in the kidney cleared rapidly from 4 to 24 h p.i. As a consequence, by 24 h p.i., the tumor-to-kidney ratio exceeds 2, and the predicted dose to tumors is significantly greater than the dose to kidneys. [64Cu]Cu-RPS-085 combines rapid tissue distribution and clearance with prolonged retention in LNCaP tumor xenografts. The pharmacokinetics should enable radioligand therapy using [67Cu]Cu-RPS-085. By virtue of its rapid kidney clearance, the therapeutic index of [67Cu]Cu-RPS-085 likely compares favorably to its parent structure, [177Lu]Lu-RPS-063, a highly avid PSMA-targeting compound. On this basis, [64/67Cu]Cu-RPS-085 show great promise as PSMA-targeting theranostic ligands for prostate cancer imaging and therapy.
Collapse
Affiliation(s)
- James M Kelly
- Division of Radiopharmaceutical Sciences and MI3 Institute, Department of Radiology, Weill Cornell Medicine, New York, New York 10021, United States
| | - Shashikanth Ponnala
- Division of Radiopharmaceutical Sciences and MI3 Institute, Department of Radiology, Weill Cornell Medicine, New York, New York 10021, United States
| | - Alejandro Amor-Coarasa
- Division of Radiopharmaceutical Sciences and MI3 Institute, Department of Radiology, Weill Cornell Medicine, New York, New York 10021, United States
| | - Nicholas A Zia
- School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Victoria 3010, Australia
| | - Anastasia Nikolopoulou
- Division of Radiopharmaceutical Sciences and MI3 Institute, Department of Radiology, Weill Cornell Medicine, New York, New York 10021, United States.,Citigroup Biomedical Imaging Center, Weill Cornell Medicine, New York, New York 10021, United States
| | - Clarence Williams
- Division of Radiopharmaceutical Sciences and MI3 Institute, Department of Radiology, Weill Cornell Medicine, New York, New York 10021, United States
| | - David J Schlyer
- Brookhaven National Laboratory, Upton, New York 11973, United States.,Department of Biomedical Engineering, Stony Brook University, Stony Brook, New York 11794, United States
| | - Stephen G DiMagno
- College of Pharmacy, University of Illinois-Chicago, Chicago, Illinois 60612, United States
| | - Paul S Donnelly
- School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Victoria 3010, Australia
| | - John W Babich
- Division of Radiopharmaceutical Sciences and MI3 Institute, Department of Radiology, Weill Cornell Medicine, New York, New York 10021, United States.,Citigroup Biomedical Imaging Center, Weill Cornell Medicine, New York, New York 10021, United States.,Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York 10065, United States
| |
Collapse
|
23
|
Abstract
Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) and the inherent sensitivity of PET technique. A variety of radionuclides and mAbs have been exploited to develop immunoPET probes, which has been driven by the development and optimization of radiochemistry and conjugation strategies. In addition, tumor-targeting vectors with a short circulation time (e.g., Nanobody) or with an enhanced binding affinity (e.g., bispecific antibody) are being used to design novel immunoPET probes. Accordingly, several immunoPET probes, such as 89Zr-Df-pertuzumab and 89Zr-atezolizumab, have been successfully translated for clinical use. By noninvasively and dynamically revealing the expression of heterogeneous tumor antigens, immunoPET imaging is gradually changing the theranostic landscape of several types of malignancies. ImmunoPET is the method of choice for imaging specific tumor markers, immune cells, immune checkpoints, and inflammatory processes. Furthermore, the integration of immunoPET imaging in antibody drug development is of substantial significance because it provides pivotal information regarding antibody targeting abilities and distribution profiles. Herein, we present the latest immunoPET imaging strategies and their preclinical and clinical applications. We also emphasize current conjugation strategies that can be leveraged to develop next-generation immunoPET probes. Lastly, we discuss practical considerations to tune the development and translation of immunoPET imaging strategies.
Collapse
Affiliation(s)
- Weijun Wei
- Department of Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, 1111 Highland Avenue, Room 7137, Madison, Wisconsin 53705, United States
| | - Zachary T Rosenkrans
- Department of Pharmaceutical Sciences, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States
| | - Jianjun Liu
- Department of Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
| | - Gang Huang
- Department of Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
- Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai 201318, China
| | - Quan-Yong Luo
- Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China
| | - Weibo Cai
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, 1111 Highland Avenue, Room 7137, Madison, Wisconsin 53705, United States
- Department of Pharmaceutical Sciences, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States
- University of Wisconsin Carbone Cancer Center, Madison, Wisconsin 53705, United States
| |
Collapse
|
24
|
Greifenstein L, Späth D, Sinnes JP, Grus T, Rösch F. Mild and efficient 64Cu labeling of perhydro-1, 4-diazepine derivatives for potential use with large peptides, proteins and antibodies. RADIOCHIM ACTA 2020. [DOI: 10.1515/ract-2019-3167] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Abstract
DATA (6-Amino-1,4-diazapine-triacetate) and AAZTA (6-Amino-1,4-diazapine-tetracetate) chelators represent a novel approach representing hybrid-chelates: possessing significant cyclic and acyclic character. It is believed that flexibility of the acyclic part facilitates rapid complexation, whilst the preorganized cyclic part minimizes the energy barrier to complexation and inhibits decomplexation processes. So far, these chelators have been used exclusively with 44Sc and 68Ga only. Recent results with natCu predict high stabilities for Cu-AAZTA, yet no radioactive labeling of AAZTA or DATA with 64Cu or any additional radioactive isotope has been reported. We present the one pot synthesis of the bifunctional derivatives AAZTA5OMe and DATA5mOMe and their labeling with 64Cu. In addition, in vitro stability of the respective complexes are presented.
Collapse
Affiliation(s)
- Lukas Greifenstein
- Institute of Nuclear Chemistry , Johannes Gutenberg University , Fritz-Straßmann-Weg 2 , 55128 Mainz , Germany
| | - Denise Späth
- Institute of Nuclear Chemistry , Johannes Gutenberg University , Fritz-Straßmann-Weg 2 , 55128 Mainz , Germany
| | - Jean Phillip Sinnes
- Institute of Nuclear Chemistry , Johannes Gutenberg University , Fritz-Straßmann-Weg 2 , 55128 Mainz , Germany
| | - Tilmann Grus
- Institute of Nuclear Chemistry , Johannes Gutenberg University , Fritz-Straßmann-Weg 2 , 55128 Mainz , Germany
| | - Frank Rösch
- Institute of Nuclear Chemistry , Johannes Gutenberg University , Fritz-Straßmann-Weg 2 , 55128 Mainz , Germany
| |
Collapse
|
25
|
Pupillo G, Mou L, Martini P, Pasquali M, Boschi A, Cicoria G, Duatti A, Haddad F, Esposito J. Production of 67Cu by enriched 70Zn targets: first measurements of formation cross sections of 67Cu, 64Cu, 67Ga, 66Ga, 69mZn and 65Zn in interactions of 70Zn with protons above 45 MeV. RADIOCHIM ACTA 2020. [DOI: 10.1515/ract-2019-3199] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
Abstract
Despite its insufficient availability, Copper-67 is currently attracting much attention for its enormous potential for cancer therapy as theranostic radionuclide. This work aims to accurately measure the unexplored cross section 70Zn(p,x)67Cu in the energy range 45–70 MeV and to evaluate its potential advantages in the case of high-intensity proton beams provided by compact cyclotrons. Thin target foils of enriched 70Zn were manufactured by lamination at the INFN-LNL and irradiated at the ARRONAX facility using the stacked-foils method. A radiochemical procedure for the separation of Cu, Ga and Zn contaminants and the isolation of 67Cu from the irradiated material was developed. The efficiency of the chemical processing was determined for each foil by monitoring the activity of selected tracer radionuclides (61Cu, 66Ga and 69mZn) through γ-spectrometry. Experimental data of the 70Zn(p,x)67Cu, 64Cu, 67Ga, 66Ga, 69mZn, 65Zn cross sections were measured for the first time in the energy range 45–70 MeV and compared with the theoretical results obtained by using the TALYS code. The 67Cu production yield by using enriched 70Zn thick targets was compared with the results obtained by using 68Zn targets in the same irradiation conditions.
Collapse
Affiliation(s)
- Gaia Pupillo
- Istituto Nazionale di Fisica Nucleare, Laboratori Nazionali di Legnaro (INFN-LNL) , Viale dell’Università 2 , Legnaro (PD) , Italy
| | - Liliana Mou
- Istituto Nazionale di Fisica Nucleare, Laboratori Nazionali di Legnaro (INFN-LNL) , Viale dell’Università 2 , Legnaro (PD) , Italy
| | - Petra Martini
- Istituto Nazionale di Fisica Nucleare, Laboratori Nazionali di Legnaro (INFN-LNL) , Viale dell’Università 2 , Legnaro (PD) , Italy
- Department of Morphology, Surgical and Experimental Medicine , University of Ferrara , Ferrara , Italy
| | - Micòl Pasquali
- Istituto Nazionale di Fisica Nucleare, Laboratori Nazionali di Legnaro (INFN-LNL) , Viale dell’Università 2 , Legnaro (PD) , Italy
- Department of Morphology, Surgical and Experimental Medicine , University of Ferrara , Ferrara , Italy
| | - Alessandra Boschi
- Department of Chemical and Pharmaceutical Sciences , University of Ferrara , Ferrara , Italy
| | | | - Adriano Duatti
- Department of Chemical and Pharmaceutical Sciences , University of Ferrara , Ferrara , Italy
| | - Férid Haddad
- GIP ARRONAX, Saint-Herblain and Laboratoire Subatech, IN2P3-CNRS, Ecole des Mines de Nantes , Université de Nantes , France
| | - Juan Esposito
- Istituto Nazionale di Fisica Nucleare, Laboratori Nazionali di Legnaro (INFN-LNL) , Viale dell’Università 2 , Legnaro (PD) , Italy
| |
Collapse
|
26
|
Karimi Z, Sadeghi M, Hosseini SF. Experimental production and theoretical assessment of 67Cu via neutron induced reaction. ANN NUCL ENERGY 2019. [DOI: 10.1016/j.anucene.2019.07.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
27
|
Ohya T, Nagatsu K, Hanyu M, Minegishi K, Zhang MR. Simple separation of 67Cu from bulk zinc by coprecipitation using hydrogen sulfide gas and silver nitrate. RADIOCHIM ACTA 2019. [DOI: 10.1515/ract-2019-3168] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Abstract
Copper-67 (67Cu), a feasible radionuclide for diagnosis and radiotherapy, is commercially generated from a bulk zinc (Zn) target using the 68Zn(p, 2p)67Cu and 68Zn(γ, p)67Cu nuclear reactions. Because it uses a large amount of zinc, the separation is complex – requiring a combination of three ion exchange columns – and is time-consuming (about 1 day). We developed a quick and easy separation method referred to as “double coprecipitation” using H2S gas and silver nitrate as coprecipitation agents in place of ion exchange columns. We compared this method with a conventional separation method using three ion exchange columns (AG50W-X8, AG1-X8, and Chelex-100) for a natural zinc (natZn) target irradiated by a proton beam. The product quality and the recovery rate with the new method were competitive with the conventional method, and the total operation time was reduced from 1 day to <3 h.
Collapse
Affiliation(s)
- Tomoyuki Ohya
- Department of Radiopharmaceuticals Development , National Institutes for Quantum and Radiological Science and Technology (NIRS-QST) , 4-9-1 Anagawa, Inage-ku , Chiba 263-8555 , Japan
| | - Kotaro Nagatsu
- National Institutes for Quantum and Radiological Science and Technology (NIRS-QST) , 4-9-1 Anagawa, Inage-ku , Chiba 263-8555 , Japan
| | - Masayuki Hanyu
- National Institutes for Quantum and Radiological Science and Technology (NIRS-QST) , 4-9-1 Anagawa, Inage-ku , Chiba 263-8555 , Japan
| | - Katsuyuki Minegishi
- National Institutes for Quantum and Radiological Science and Technology (NIRS-QST) , 4-9-1 Anagawa, Inage-ku , Chiba 263-8555 , Japan
| | - Ming-Rong Zhang
- National Institutes for Quantum and Radiological Science and Technology (NIRS-QST) , 4-9-1 Anagawa, Inage-ku , Chiba 263-8555 , Japan
| |
Collapse
|
28
|
Mikolajczak R, van der Meulen NP, Lapi SE. Radiometals for imaging and theranostics, current production, and future perspectives. J Labelled Comp Radiopharm 2019; 62:615-634. [PMID: 31137083 DOI: 10.1002/jlcr.3770] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2018] [Revised: 04/10/2019] [Accepted: 05/15/2019] [Indexed: 02/06/2023]
Abstract
The aim of this review is to make the reader familiar with currently available radiometals, their production modes, capacities, and quality concerns related to their medical use, as well as new emerging radiometals and irradiation technologies from the perspective of their diagnostic and theranostic applications. Production methods of 177 Lu serve as an example of various issues related to the production yield, specific activity, radionuclidic and chemical purity, and production economy. Other radiometals that are currently used or explored for potential medical applications, with particular focus on their theranostic value, are discussed. Using radiometals for diagnostic imaging and therapy is on the rise. The high demand for radiometals for medical use prompts investigations towards using alternative irradiation reactions, while using existing nuclear reactors and accelerator facilities. This review discusses these production capacities and what is necessary to cover the growing demand for theranostic nuclides.
Collapse
Affiliation(s)
- Renata Mikolajczak
- Radioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, Poland
| | | | - Suzanne E Lapi
- Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama
| |
Collapse
|
29
|
Aliev RA, Belyshev SS, Kuznetsov AA, Dzhilavyan LZ, Khankin VV, Aleshin GY, Kazakov AG, Priselkova AB, Kalmykov SN, Ishkhanov BS. Photonuclear production and radiochemical separation of medically relevant radionuclides: 67Cu. J Radioanal Nucl Chem 2019. [DOI: 10.1007/s10967-019-06576-9] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
30
|
Loveless CS, Radford LL, Ferran SJ, Queern SL, Shepherd MR, Lapi SE. Photonuclear production, chemistry, and in vitro evaluation of the theranostic radionuclide 47Sc. EJNMMI Res 2019; 9:42. [PMID: 31098710 PMCID: PMC6522578 DOI: 10.1186/s13550-019-0515-8] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2019] [Accepted: 05/03/2019] [Indexed: 12/22/2022] Open
Abstract
Background In molecular imaging and nuclear medicine, theranostic agents that integrate radionuclide pairs are successfully being used for individualized care, which has led to rapidly growing interest in their continued development. These compounds, which are radiolabeled with one radionuclide for imaging and a chemically identical or similar radionuclide for therapy, may improve patient-specific treatment and outcomes by matching the properties of different radionuclides with a targeting vector for a particular tumor type. One proposed theranostic radionuclide is scandium-47 (47Sc, T1/2 = 3.35 days), which can be used for targeted radiotherapy and may be paired with the positron emitting radionuclides, 43Sc (T1/2 = 3.89 h) and 44Sc (T1/2 = 3.97 h) for imaging. The aim of this study was to investigate the photonuclear production of 47Sc via the 48Ti(γ,p)47Sc reaction using an electron linear accelerator (eLINAC), separation and purification of 47Sc, the radiolabeling of somatostatin receptor-targeting peptide DOTATOC with 47Sc, and in vitro receptor-mediated binding of [47Sc]Sc-DOTATOC in AR42J somatostatin receptor subtype two (SSTR2) expressing rat pancreatic tumor cells. Results The rate of 47Sc production in a stack of natural titanium foils (n = 39) was 8 × 107 Bq/mA·h (n = 3). Irradiated target foils were dissolved in 2.0 M H2SO4 under reflux. After dissolution, trivalent 47Sc ions were separated from natural Ti using AG MP-50 cation exchange resin. The recovered 47Sc was then purified using CHELEX 100 ion exchange resin. The average decay-corrected two-step 47Sc recovery (n = 9) was (77 ± 7)%. A radiolabeling yield of > 99.9% of [47Sc]Sc-DOTATOC (0.384 mg in 0.3 mL) was achieved using 1.7 MBq of 47Sc. Blocking studies using Octreotide illustrated receptor-mediated uptake of [47Sc]Sc-DOTATOC in AR42J cells. Conclusions 47Sc can be produced via the 48Ti(γ,p)47Sc reaction and separated from natural Ti targets with a yield and radiochemical purity suitable for radiolabeling of peptides for in vitro studies. The data in this work supports the potential use of eLINACs for studies of photonuclear production of medical radionuclides and the future development of high-intensity eLINAC facilities capable of producing relevant quantities of carrier-free radionuclides currently inaccessible via routine production pathways or limited due to costly enriched targets. Electronic supplementary material The online version of this article (10.1186/s13550-019-0515-8) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- C Shaun Loveless
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, 35233, USA.,Department of Chemistry, Washington University in St. Louis, St. Louis, MO, 63134, USA
| | - Lauren L Radford
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, 35233, USA
| | - Samuel J Ferran
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, 35233, USA.,Department of Chemistry, University of Alabama at Birmingham, Birmingham, AL, 35233, USA
| | - Stacy L Queern
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, 35233, USA.,Department of Chemistry, Washington University in St. Louis, St. Louis, MO, 63134, USA
| | | | - Suzanne E Lapi
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, 35233, USA. .,Department of Chemistry, Washington University in St. Louis, St. Louis, MO, 63134, USA. .,Department of Chemistry, University of Alabama at Birmingham, Birmingham, AL, 35233, USA.
| |
Collapse
|
31
|
Souliotis GA, Rodrigues MRD, Wang K, Iacob VE, Nica N, Roeder B, Tabacaru G, Yu M, Zanotti-Fregonara P, Bonasera A. A novel approach to medical radioisotope production using inverse kinematics: A successful production test of the theranostic radionuclide 67Cu. Appl Radiat Isot 2019; 149:89-95. [PMID: 31035108 DOI: 10.1016/j.apradiso.2019.04.019] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2019] [Revised: 03/31/2019] [Accepted: 04/16/2019] [Indexed: 11/28/2022]
Abstract
A novel method for the production of important medical radioisotopes has been developed. The approach is based on performing the nuclear reaction in inverse kinematics, namely sending a heavy-ion beam of appropriate energy on a light target (e.g. H, d, He) and collecting the isotope of interest. In this work, as a proof-of-concept, we studied the production of the theranostic radionuclide 67Cu (T1/2 = 62 h) via the reaction of a 70Zn beam at 15 MeV/nucleon with a hydrogen gas target. The 67Cu radionuclide alongside other coproduced isotopes, was collected after the gas target on an aluminum catcher foil and their radioactivity was measured by off-line γ-ray analysis. After 36 h post irradiation, apart from the product of interest 67Cu, the main radioimpurity coming from the 70Zn + p reaction was 69mZn (T1/2 = 13.8 h), which can be reduced by further radio-cooling. Moreover, along with the radionuclide of interest produced in inverse kinematics, the production of additional radioisotopes is possible by making use of the forward-focused neutrons from the reaction and allowing them to interact with a secondary target. A preliminary successful test of this concept was realized in the present study. The main requirement to obtain activities appropriate for preclinical studies is the development of high-intensity heavy-ion primary beams.
Collapse
Affiliation(s)
- G A Souliotis
- Laboratory of Physical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Athens, 15771, Greece.
| | - M R D Rodrigues
- Cyclotron Institute, Texas A&M University, College Station, TX, 77843, USA; Instituto de Física, Universidade de São Paulo, São Paulo, 05508-090, Brazil
| | - K Wang
- Cyclotron Institute, Texas A&M University, College Station, TX, 77843, USA
| | - V E Iacob
- Cyclotron Institute, Texas A&M University, College Station, TX, 77843, USA
| | - N Nica
- Cyclotron Institute, Texas A&M University, College Station, TX, 77843, USA
| | - B Roeder
- Cyclotron Institute, Texas A&M University, College Station, TX, 77843, USA
| | - G Tabacaru
- Cyclotron Institute, Texas A&M University, College Station, TX, 77843, USA
| | - M Yu
- Houston Methodist Research Institute, Houston, TX, 77030, USA
| | | | - A Bonasera
- Cyclotron Institute, Texas A&M University, College Station, TX, 77843, USA; Laboratori Nazionali del Sud, INFN, Catania, 95123, Italy
| |
Collapse
|
32
|
Calculation of productions of medical 201Pb, 198Au, 186Re, 111Ag, 103Pd, 90Y, 89Sr, 77Kr, 77As, 67Cu, 64Cu, 47Sc and 32P nuclei used in cancer therapy via phenomenological and microscopic level density models. Appl Radiat Isot 2019; 144:64-79. [DOI: 10.1016/j.apradiso.2018.11.011] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2018] [Revised: 10/12/2018] [Accepted: 11/22/2018] [Indexed: 11/24/2022]
|
33
|
Perspectives on the Use of Liquid Extraction for Radioisotope Purification. Molecules 2019; 24:molecules24020334. [PMID: 30669256 PMCID: PMC6359044 DOI: 10.3390/molecules24020334] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2018] [Accepted: 01/11/2019] [Indexed: 01/08/2023] Open
Abstract
The reliable and efficient production of radioisotopes for diagnosis and therapy is becoming an increasingly important capability, due to their demonstrated utility in Nuclear Medicine applications. Starting from the first processes involving the separation of 99mTc from irradiated materials, several methods and concepts have been developed to selectively extract the radioisotopes of interest. Even though the initial methods were based on liquid-liquid extraction (LLE) approaches, the perceived difficulty in automating such processes has slowly moved the focus towards resin separation methods, whose basic chemical principles are often similar to the LLE ones in terms of chelators and phases. However, the emerging field of flow chemistry allows LLE to be easily automated and operated in a continuous manner, resulting in an even improved efficiency and reliability. In this contribution, we will outline the fundamentals of LLE processes and their translation into flow-based apparatuses; in addition, we will provide examples of radioisotope separations that have been achieved using LLE methods. This article is intended to offer insights about the future potential of LLE to purify medically relevant radioisotopes.
Collapse
|
34
|
|
35
|
Abstract
Nuclear medicine is composed of two complementary areas, imaging and therapy. Positron emission tomography (PET) and single-photon imaging, including single-photon emission computed tomography (SPECT), comprise the imaging component of nuclear medicine. These areas are distinct in that they exploit different nuclear decay processes and also different imaging technologies. In PET, images are created from the 511 keV photons produced when the positron emitted by a radionuclide encounters an electron and is annihilated. In contrast, in single-photon imaging, images are created from the γ rays (and occasionally X-rays) directly emitted by the nucleus. Therapeutic nuclear medicine uses particulate radiation such as Auger or conversion electrons or β- or α particles. All three of these technologies are linked by the requirement that the radionuclide must be attached to a suitable vector that can deliver it to its target. It is imperative that the radionuclide remain attached to the vector before it is delivered to its target as well as after it reaches its target or else the resulting image (or therapeutic outcome) will not reflect the biological process of interest. Radiochemistry is at the core of this process, and radiometals offer radiopharmaceutical chemists a tremendous range of options with which to accomplish these goals. They also offer a wide range of options in terms of radionuclide half-lives and emission properties, providing the ability to carefully match the decay properties with the desired outcome. This Review provides an overview of some of the ways this can be accomplished as well as several historical examples of some of the limitations of earlier metalloradiopharmaceuticals and the ways that new technologies, primarily related to radionuclide production, have provided solutions to these problems.
Collapse
Affiliation(s)
- Eszter Boros
- Department of Chemistry , Stony Brook University , Stony Brook , New York 11794 , United States
| | - Alan B Packard
- Division of Nuclear Medicine and Molecular Imaging, Department of Radiology , Boston Children's Hospital , Boston , Massachusetts 02115 , United States.,Harvard Medical School , Boston , Massachusetts 02115 , United States
| |
Collapse
|
36
|
Ahmedova A, Todorov B, Burdzhiev N, Goze C. Copper radiopharmaceuticals for theranostic applications. Eur J Med Chem 2018; 157:1406-1425. [DOI: 10.1016/j.ejmech.2018.08.051] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2018] [Revised: 08/15/2018] [Accepted: 08/18/2018] [Indexed: 12/12/2022]
|
37
|
Retracted: The Copper Radioisotopes: A Systematic Review with Special Interest to 64Cu. BIOMED RESEARCH INTERNATIONAL 2018; 2018:3860745. [PMID: 30069467 PMCID: PMC6057420 DOI: 10.1155/2018/3860745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 05/01/2018] [Accepted: 05/01/2018] [Indexed: 11/18/2022]
|
38
|
Ohya T, Nagatsu K, Suzuki H, Fukada M, Minegishi K, Hanyu M, Zhang MR. Small-scale production of 67 Cu for a preclinical study via the 64 Ni(α, p) 67 Cu channel. Nucl Med Biol 2018; 59:56-60. [DOI: 10.1016/j.nucmedbio.2018.01.002] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2017] [Revised: 01/23/2018] [Accepted: 01/23/2018] [Indexed: 10/18/2022]
|
39
|
Gopalakrishna A, Suryanarayana SV, Naik H, Dixit TS, Nayak BK, Kumar A, Maletha P, Thakur K, Deshpande A, Krishnan R, Kamaldeep, Banerjee S, Saxena A. Production, separation and supply prospects of 67Cu with the development of fast neutron sources and photonuclear technology. RADIOCHIM ACTA 2018. [DOI: 10.1515/ract-2017-2847] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
Experimental investigations have been carried out on the production of a promising therapeutic radionuclide 67Cu via the 67Zn(n,p)67Cu, 68Zn(n,x)67Cu, and 68Zn(γ,p)67Cu reaction routes. Natural zinc metal foils were irradiated with 14.1 MeV neutrons and bremsstrahlung of end-point energy 15 MeV. Radioactivity levels of 67Cu and other radioisotopes co-produced were determined by the quantification of photo-peaks by off-line γ-ray spectrometry. No carrier added 67Cu was separated from the irradiated zinc by solvent extraction. Yields >90% and high levels of radionuclidic purity were achieved. These studies indicate that the growth and development of intense fast neutron sources and photonuclear technology, will possibly aid in the sustained supply of 67Cu.
Collapse
Affiliation(s)
- Arjun Gopalakrishna
- Medical Cyclotron Facility, Board of Radiation and Isotope Technology , Mumbai 400012 , India
- Physical and Mathematical Sciences, Homi Bhabha National Institute , Mumbai 400094 , India
| | | | - Haladhara Naik
- Radiochemistry Division, Bhabha Atomic Research Centre , Mumbai 400085 , India
| | - Tanuja Sushant Dixit
- Society for Applied Microwave Electronics Engineering and Research, IIT Campus , Mumbai 400076 , India
| | - Basant Kumar Nayak
- Nuclear Physics Division, Bhabha Atomic Research Centre , Mumbai 400085 , India
| | - Amit Kumar
- Medical Cyclotron Facility, Board of Radiation and Isotope Technology , Mumbai 400012 , India
| | - Pravind Maletha
- Radiation Medicine Centre, Bhabha Atomic Research Centre , Mumbai 400 012 , India
| | - Kiran Thakur
- Society for Applied Microwave Electronics Engineering and Research, IIT Campus , Mumbai 400076 , India
| | - Abhay Deshpande
- Society for Applied Microwave Electronics Engineering and Research, IIT Campus , Mumbai 400076 , India
| | - Ramamoorthy Krishnan
- Society for Applied Microwave Electronics Engineering and Research, IIT Campus , Mumbai 400076 , India
| | - Kamaldeep
- Radiation Medicine Centre, Bhabha Atomic Research Centre , Mumbai 400 012 , India
| | - Sharmila Banerjee
- Radiation Medicine Centre, Bhabha Atomic Research Centre , Mumbai 400 012 , India
| | - Alok Saxena
- Nuclear Physics Division, Bhabha Atomic Research Centre , Mumbai 400085 , India
| |
Collapse
|
40
|
Qaim SM, Spahn I. Development of novel radionuclides for medical applications. J Labelled Comp Radiopharm 2017; 61:126-140. [PMID: 29110328 DOI: 10.1002/jlcr.3578] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2017] [Revised: 10/20/2017] [Accepted: 10/24/2017] [Indexed: 11/12/2022]
Abstract
Medical radionuclide production technology is well established. There is, however, a constant need for further development of radionuclides. The present efforts are mainly devoted to nonstandard positron emitters (eg, 64 Cu, 86 Y, 124 I, and 73 Se) and novel therapeutic radionuclides emitting low-range β- particles (eg, 67 Cu and 186 Re), conversion or Auger electrons (eg, 117m Sn and 77 Br), and α particles (eg, 225 Ac). A brief account of various aspects of development work (ie, nuclear data, targetry, chemical processing, and quality control) is given. For each radionuclide under consideration, the status of technology for clinical scale production is discussed. The increasing need of intermediate-energy multiple-particle accelerating cyclotrons is pointed out.
Collapse
Affiliation(s)
- Syed M Qaim
- Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich, Jülich, Germany
| | - Ingo Spahn
- Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich, Jülich, Germany
| |
Collapse
|
41
|
Uddin MS, Kim K, Nadeem M, Sudár S, Kim G. Measurements of excitation functions of α-particle induced reactions on natNi: possibility of production of the medical isotopes 61Cu and 67Cu. RADIOCHIM ACTA 2017. [DOI: 10.1515/ract-2017-2837] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
Excitation functions of the natNi(α,x)60,61Cu and 64Ni(α,p)67Cu reactions were measured using the stacked-foil activation technique. The experimental data achieved were compared with literature data as well as with nuclear model calculations performed using the code TALYS-1.8. Integral yields from the respective thresholds to 44 MeV were deduced from the measured excitation curves. The >99% pure 61Cu can be produced using the energy window of Eα=20→7 MeV, the yield amounting to 116 MBq/μAh. After a 2 h cooling time, the short-lived 60Cu (T1/2=23 min) impurity will be reduced to <0.1%. Due to low isotopic abundance of 64Ni, the enriched 64Ni target would be needed for the production of 67Cu via the (α,p) reaction. The cost would, however, be very high. In a few cases, particularly above 24 MeV, we have given new data points. In general, our measurements have strengthened the database.
Collapse
Affiliation(s)
- Md. Shuza Uddin
- Tandem Accelerator Facilities, Institute of Nuclear Science and Technology, Atomic Energy Research Establishment , Savar, Dhaka , Bangladesh
| | - Kwangsoo Kim
- Department of Physics , Kyungpook National University , 80 Daehak-ro, Buk-gu , Daegu 41566 , Republic of Korea
| | - Muhammad Nadeem
- Department of Physics , Kyungpook National University , 80 Daehak-ro, Buk-gu , Daegu 41566 , Republic of Korea
| | - Sandor Sudár
- Institute of Experimental Physics, Debrecen University , H-4001 Debrecen , Hungary
| | - Guinyun Kim
- Department of Physics , Kyungpook National University , 80 Daehak-ro, Buk-gu , Daegu 41566 , Republic of Korea
| |
Collapse
|
42
|
Müller C, van der Meulen NP, Benešová M, Schibli R. Therapeutic Radiometals Beyond 177Lu and 90Y: Production and Application of Promising α-Particle, β−-Particle, and Auger Electron Emitters. J Nucl Med 2017; 58:91S-96S. [DOI: 10.2967/jnumed.116.186825] [Citation(s) in RCA: 47] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2017] [Accepted: 03/13/2017] [Indexed: 12/31/2022] Open
|
43
|
Abstract
At present, 64Cu(II) labeled tracers including 64CuCl2 have been widely applied in the research of molecular imaging and therapy. Human copper transporter 1 (hCTR1) is the major high affinity copper influx transporter in mammalian cells, and specially responsible for the transportation of Cu(I) not Cu(II). Thus, we investigated the feasible application of 64Cu(I) for PET imaging. 64Cu(II) was reduced to 64Cu(I) with the existence of sodium L-ascorbate, DL-Dithiothreitol or cysteine. Cell uptake and efflux assay was investigated using B16F10 and A375 cell lines, respectively. Small animal PET and biodistribution studies were performed in both B16F10 and A375 tumor-bearing mice. Compared with 64Cu(II), 64Cu(I) exhibited higher cellular uptake by melanoma, which testified CTR1 specially influx of Cu(I). However, due to oxidation reaction in vivo, no significant difference between 64Cu(I) and 64Cu(II) was observed through PET images and biodistribution. Additionally, radiation absorbed doses for major tissues of human were calculated based on the mouse biodistribution. Radiodosimetry calculations for 64/67Cu(I) and 64/67Cu(II) were similar, which suggested that although melanoma were with high radiation absorbed doses, high radioactivity accumulation by liver and kidney should be noticed for the further application. Thus, 64Cu(I) should be further studied to evaluate it as a PET imaging radiotracer.
Collapse
|
44
|
67Cu-Radiolabeling of a multimeric RGD peptide for αVβ3 integrin-targeted radionuclide therapy. Nucl Med Commun 2017; 38:347-355. [DOI: 10.1097/mnm.0000000000000646] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
45
|
Baum RP, Singh A, Benešová M, Vermeulen C, Gnesin S, Köster U, Johnston K, Müller D, Senftleben S, Kulkarni HR, Türler A, Schibli R, Prior JO, van der Meulen NP, Müller C. Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with 152Tb-DOTATOC. Dalton Trans 2017; 46:14638-14646. [DOI: 10.1039/c7dt01936j] [Citation(s) in RCA: 45] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The existence of theragnostic pairs of radionuclides allows the preparation of radiopharmaceuticals for diagnostic and therapeutic purposes.
Collapse
|
46
|
Qaim SM. Nuclear data for production and medical application of radionuclides: Present status and future needs. Nucl Med Biol 2016; 44:31-49. [PMID: 27821344 DOI: 10.1016/j.nucmedbio.2016.08.016] [Citation(s) in RCA: 107] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2016] [Revised: 08/22/2016] [Accepted: 08/23/2016] [Indexed: 11/30/2022]
Abstract
INTRODUCTION The significance of nuclear data in the choice and medical application of a radionuclide is considered: the decay data determine its suitability for organ imaging or internal therapy and the reaction cross section data allow optimisation of its production route. A brief discussion of reaction cross sections and yields is given. STANDARD RADIONUCLIDES The standard SPECT, PET and therapeutic radionuclides are enumerated and their decay and production data are considered. The status of nuclear data is generally good. Some existing discrepancies are outlined. A few promising alternative production routes of 99mTc and 68Ga are discussed. RESEARCH-ORIENTED RADIONUCLIDES The increasing significance of non-standard positron emitters in organ imaging and of low-energy highly-ionizing radiation emitters in internal therapy is discussed, their nuclear data are considered and a brief review of their status is presented. Some other related nuclear data issues are also mentioned. PRODUCTION OF RADIONUCLIDES USING NEWER TECHNOLOGIES The data needs arising from new directions in radionuclide applications (multimode imaging, theranostic approach, radionanoparticles, etc.) are considered. The future needs of data associated with possible utilization of newer irradiation technologies (intermediate energy cyclotron, high-intensity photon accelerator, spallation neutron source, etc.) are outlined. CONCLUSION Except for a few small discrepancies, the available nuclear data are sufficient for routine production and application of radionuclides. Considerable data needs exist for developing novel radionuclides for applications. The developing future technologies for radionuclide production will demand further data-related activities.
Collapse
Affiliation(s)
- Syed M Qaim
- Institut für Neurowissenschaften und Medizin, INM-5 (Nuklearchemie), Forschungszentrum Jülich, D-52425 Jülich, Germany.
| |
Collapse
|
47
|
Mastren T, Pen A, Loveless S, Marquez BV, Bollinger E, Marois B, Hubley N, Brown K, Morrissey DJ, Peaslee GF, Lapi SE. Harvesting 67Cu from the Collection of a Secondary Beam Cocktail at the National Superconducting Cyclotron Laboratory. Anal Chem 2015; 87:10323-9. [DOI: 10.1021/acs.analchem.5b02322] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Tara Mastren
- Department
of Chemistry, Washington University in St. Louis, One Brookings
Drive, St. Louis, Missouri 63139, United States
- Department
of Radiology, Washington University School of Medicine, 510 S. Kingshighway
Boulevard, St. Louis, Missouri 63110, United States
| | - Aranh Pen
- Department
of Chemistry, Hope College, 35 East 12th Street, Holland, Michigan 49422, United States
| | - Shaun Loveless
- Department
of Radiology, Washington University School of Medicine, 510 S. Kingshighway
Boulevard, St. Louis, Missouri 63110, United States
| | - Bernadette V. Marquez
- Department
of Radiology, Washington University School of Medicine, 510 S. Kingshighway
Boulevard, St. Louis, Missouri 63110, United States
| | - Elizabeth Bollinger
- Department
of Radiology, Washington University School of Medicine, 510 S. Kingshighway
Boulevard, St. Louis, Missouri 63110, United States
| | - Boone Marois
- Department
of Chemistry, Hope College, 35 East 12th Street, Holland, Michigan 49422, United States
| | - Nicholas Hubley
- Department
of Chemistry, Hope College, 35 East 12th Street, Holland, Michigan 49422, United States
| | - Kyle Brown
- Department
of Chemistry, Washington University in St. Louis, One Brookings
Drive, St. Louis, Missouri 63139, United States
| | - David J. Morrissey
- Department
of Chemistry, Michigan State University, 578 South Shaw Lane, East Lansing, Michigan 48824, United States
| | - Graham F. Peaslee
- Department
of Chemistry, Hope College, 35 East 12th Street, Holland, Michigan 49422, United States
| | - Suzanne E. Lapi
- Department
of Chemistry, Washington University in St. Louis, One Brookings
Drive, St. Louis, Missouri 63139, United States
- Department
of Radiology, Washington University School of Medicine, 510 S. Kingshighway
Boulevard, St. Louis, Missouri 63110, United States
| |
Collapse
|
48
|
Johnsen AM, Heidrich BJ, Durrant CB, Bascom AJ, Ünlü K. Reactor production of 64Cu and 67Cu using enriched zinc target material. J Radioanal Nucl Chem 2015. [DOI: 10.1007/s10967-015-4032-6] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
49
|
|
50
|
Feasibility of isotope harvesting at a projectile fragmentation facility: ⁶⁷Cu. Sci Rep 2014; 4:6706. [PMID: 25330839 PMCID: PMC4204030 DOI: 10.1038/srep06706] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2014] [Accepted: 10/02/2014] [Indexed: 11/08/2022] Open
Abstract
The work presented here describes a proof-of-principle experiment for the chemical extraction of (67)Cu from an aqueous beam stop at the National Superconducting Cyclotron Laboratory (NSCL). A 76 MeV/A (67)Cu beam was stopped in water, successfully isolated from the aqueous solution through a series of chemical separations involving a chelating disk and anion exchange chromatography, then bound to NOTA-conjugated Herceptin antibodies, and the bound activity was validated using instant thin-layer chromatography (ITLC). The chemical extraction efficiency was found to be 88 ± 3% and the radiochemical yield was ≥95%. These results show that extraction of radioisotopes from an aqueous projectile-fragment beam dump is a feasible method for obtaining radiochemically pure isotopes.
Collapse
|